Business Wire

UK Corporate Compliance Expert Peter Burrell to Join Willkie as a Partner in London

Share
NY-WILLKIE-FARR

Firm significantly expands international Compliance and Enforcement Practice

Willkie Farr & Gallagher LLP has announced that UK solicitor Peter Burrell will join the firm as a partner in London. Mr. Burrell, the head of Herbert Smith’s Investigations and Corporate Crimes Practice, is recognized internationally as a leading authority on anti-corruption and white collar criminal matters. His broad experience and expertise in this area will greatly enhance Willkie’s ability to assist clients in complying with the new UK Bribery Act. The Act, which completely overhauls UK anti-corruption law, exposes companies doing business in the UK and abroad to criminal liability and potentially severe penalties if they fail to comply with its stringent provisions.

Mr. Burrell specializes in complex and contentious regulatory matters, including conducting and managing internal investigations, either commenced as a result of an internal discovery or in response to an external investigation by the UK Serious Fraud Office (SFO), HM Revenue & Customs, Department for Business, Innovation and Skills, or the Financial Services Authority. He also advises clients on controls and procedures regarding money laundering and financial crime prevention, and on criminal liability issues, with a particular focus on anti-corruption policies and procedures. Mr. Burrell is regularly sought to manage and conduct criminal investigations and proceedings, as well as acting for clients in associated civil litigation. He has handled some of the most noteworthy SFO prosecutions, including acting for Severn Trent Plc and Mabey & Johnson in the SFO’s first prosecution of a company for overseas corruption and the first use of the Attorney General’s Plea Bargaining Guidelines.

Tom Cerabino, co-chair of Willkie Farr & Gallagher, said “We are delighted to have a solicitor with Peter’s credentials and reputation join us in London. Recruiting Peter is one further step in the development and expansion of our European network, and we look forward to working with Peter to expand our highly regarded practice in the compliance and enforcement area.”

Martin Weinstein, who chairs the firm’s Compliance and Enforcement Practice stated: “The UK Bribery Act is expected to have a significant impact on global anti-corruption compliance by multinational companies. Willkie already has one of the preeminent U.S.-based anti-corruption practices. With the addition of Peter in London, we will have market-leading expertise on both sides of the Atlantic. We look forward to working with Peter to provide the very best team to service our multinational clients’ needs.”

Willkie’s Compliance and Enforcement Practice, recognized globally as among the very best in the field, includes a number of former U.S. Department of Justice prosecutors and two former SEC Assistant Directors. Willkie’s significant FCPA experience, successes and overall knowledge base place it among a select few international firms that will be prepared to assist clients with the increasingly complex risks and challenges associated with international anti-corruption compliance and enforcement. Mr. Burrell is expected to join the firm as soon as he is free to do so under his existing arrangements with Herbert Smith.

Willkie Farr & Gallagher LLP is an international law firm of approximately 630 attorneys with offices in New York, Washington, Paris, London, Milan, Rome, Frankfurt and Brussels. The firm is headquartered in New York City at 787 Seventh Avenue. Tel: 212.728.8000.

Contact:

Willkie Farr & Gallagher LLP
Antoinette C. McGovern, 212-728-8404
Email: amcgovern@willkie.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 09:15:00 CEST | Press release

Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i

The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release

Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP

Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release

New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release

- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P

Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release

With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye